Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | GALR3 | O60755 | 1/20 | 0.34 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29957198 | 1.00 | TAAR1 (0.46) | TAAR1ACHETSHRCYP11B1CYP11B2 | |
| SCHEMBL29957524 | 0.82 | ESR1 (0.41) | TAAR1ACHETSHRCYP11B1CYP11B2 | |
| SCHEMBL11366815 | 0.82 | HSPA5 (0.33) | — | |
| SCHEMBL29952113 | 0.77 | TAAR1 (0.54) | TAAR1ACHETSHRCHRM2PTGS1 | |
| SCHEMBL854969 | 0.76 | GABRA1 (0.41) | ALDH1A1MAPT | |
| SCHEMBL855046 | 0.74 | CYP1A2 (0.52) | TSHRALDH1A1MAPT | |
| SCHEMBL10175168 | 0.73 | TAAR1 (0.48) | TAAR1TSHRKMT2ACYP2A13LMNA | |
| SCHEMBL29953337 | 0.73 | TAAR1 (0.50) | TAAR1KMT2AHPGDLMNAALDH1A1 | |
| SCHEMBL12245650 | 0.71 | TAAR1 (0.48) | TAAR1KMT2ACYP2A13HPGDLMNA | |
| SCHEMBL6242080 | 0.71 | IDO1 (0.50) | TAAR1TSHRCHRM2LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408802-A1 | CYCLIC AMINO ACID MOLECULES AND METHODS OF PREPARING THE SAME | The Governing Council of the University of Toronto (CA) | 2012-01-25 | — | — | EP | claimed |
| WO-2010105363-A1 | CYCLIC AMINO ACID MOLECULES AND METHODS OF PREPARING THE SAME | YUDIN ANDREI (CA) | 2010-09-23 | — | — | WO | claimed |
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | AMGEN INC. (US) | 2023-09-26 | — | — | US | disclosed |
| CN-111699174-A | Spiro compound used as indoleamine-2, 3-dioxygenase inhibitor | 中国科学院上海有机化学研究所 | 2020-09-22 | — | — | CN | disclosed |
| EP-3221335-A1 | SOLID PHASE SYNTHESIS OF CYCLIC AMINO ACID MOLECULES | Encycle Therapeutics (CA) | 2017-09-27 | — | — | EP | disclosed |
| EP-2408802-B1 | CYCLIC AMINO ACID MOLECULES AND METHODS OF PREPARING THE SAME | GOVERNING COUNCIL UNIV TORONTO (CA) | 2017-05-03 | — | — | EP | disclosed |
| WO-2016079682-A1 | SOLID PHASE SYNTHESIS OF CYCLIC AMINO ACID MOLECULES | ENCYCLE THERAPEUTICS (CA) | 2016-05-26 | — | — | WO | disclosed |
| US-8852757-B2 | Organic electroluminescence element, lighting device and display device | KONICA MINOLTA HOLDINGS, INC. (JP) | 2014-10-07 | — | — | US | disclosed |
| US-8507410-B2 | Pyridazinone compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2013-08-13 | — | — | US | disclosed |
| US-8394828-B2 | Quinoline-derived amide modulators of vanilloid VR1 receptor | JANSSEN PHARMACEUTICA, NV (BE) | 2013-03-12 | — | — | US | disclosed |
| EP-2539320-A1 | A PROCESS FOR THE PREPARATION OF SUBSTITUTED PROLYL PEPTIDES AND SIMILAR PEPTIDOMIMETICS | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patiëntenzorg (NL) | 2013-01-02 | — | — | EP | disclosed |
| WO-2001051529-A1 | PROCATALYSTS COMPRISING BIDENTATE LIGANDS, CATALYST SYSTEMS, AND USE IN OLEFIN POLYMERIZATION | EASTMAN CHEMICAL COMPANY (US) | 2001-07-19 | — | — | WO | disclosed |
| WO-2000075203-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075202-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| WO-2000075204-A1 | PROCESS FOR PRODUCING ETHYLENE/OLEFIN INTERPOLYMERS | EASTMAN CHEMICAL COMPANY (US) | 2000-12-14 | — | — | WO | disclosed |
| EP-0942924-A2 | METHODS AND COMPOUNDS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022494-A9 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | — | 1998-08-20 | — | — | WO | disclosed |
| WO-1998022494-A2 | METHODS AND COMPOUNDS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1998-05-28 | — | — | WO | disclosed |
| US-5736523-A | ADMINISTERING TO THE MAMMAL SUFFERING FROM CANCER | BIOCHEM PHARMA INC. (CA) | 1998-04-07 | — | — | US | disclosed |
| US-5606037-A | Processes antineoplastic heteronaphthoquinones | BIOCHEM PHARMA INC. (CA) | 1997-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11766436-B2 | KRAS G12C inhibitors and methods of using the same | KRAS, NRAS, HRAS | TAAR1 4726/4885ACHE 4824/4885TSHR 4359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.